(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
African nations push to recognize crimes of colonialism in Algeria - 2Wizz CEO: We’re going to invest $1 b. in Israeli market
- 3Renewables cover over 50% of German electricity consumption in Q1
- 4Carry Nature Inside with These Staggering Plant Decisions
- 5Central African Republic's president sworn in for a third term after disputed election
- UN panel says Israel operating 'de facto policy of torture'
- Free Fuel Giveaway Sparks Traffic Mayhem Before Police Shut It Down
- Ukraine's naval drones are gunning for Russia's 'shadow fleet.' A security source says a tanker just suffered a critical hit.
- Pick Your Favored pizza beating
- Winter storm headed for Midwest to Northeast. Here's how much snow to expect.
- Embrace the Outside: Exercises and Entertainment
- Moon-bound Artemis II astronauts enjoy a relaxed day in space
- Fundamental Venture The board Apparatuses for Remote Groups
- The most effective method to Arrange a Higher Medical caretaker Pay During Your Next New employee screening
